News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News

Pharmaceutical Technology Europe
Volume 22, Issue 5

The end of the blockbuster era


MEL CURTIS/GETTY IMAGES
Realising that the era of blockbuster drugs is coming to an end, Big Pharma has turned its eyes to focus on a new game — orphan drugs. The pharma industry's new fascination with these drugs is highlighted in Thomson Reuters' The Ones To Watch report for October–December 2009, which examines some of the most promising drugs launched or receiving approval, and moving through each of the clinical phases, between October and December 2009.

"As we see from this quarter's selection, drugs for small patient populations have already reached the market," says the report. "Meanwhile, drugs for urea cycle disorder and multiple myeloma are moving apace through the pipeline, giving hope to patients diseases that are unlikely to ever deliver a blockbuster drug."

The report also added that, according to a January 2010 report by the Tufts Center for the Study of Drug Development, the number of drugs receiving orphan status has doubled since 2000. Meanwhile, research from BCC Research also shows that companies migrating away from blockbusters to orphans are likely to be rewarded— the orphan drugs market is expected to grow from $58.7 billion in 2006 to $81.8 billion in 2011.

Of Thomson Reuters' predicted five most promising drugs launched or receiving approval, three are treatments for rare conditions. Dyax's Kalbitor, a treatment for hereditary angioedema, which affects between 1 in 10000 and 1 in 50000, has been forecast by Thomson Pharma to achieve sales of approximately $150 million in 2013.


News bites
Meanwhile, Folotyn, developed by Allos, was granted accelerated approval by the FDA in September 2009 and launched in the US in October, and is the first treatment for relapsed or refractory periphereal Tcell lymphoma (an often aggressive type of nonHodgkins lymphoma). The report also highlighted Istodax, developed by Celgene for the treatment of cutaneous Tcell lymphoma (CTCL). The drug is the second anticancer histone deactylase inhibitor to be approved after Merck's Zolinza (also for CTCL), which, according to the report, suggests "significant potential in this class of compounds".

The other two drugs highlighted were Novartis' Onbrez Breezhaler treatment for chronic obstructory pulmonary disease, which is expected by Thomson Pharma to achieve sales of $397 million in 2013, and Theravance and Astellas' Vibativ — a treatment for complicated skin structure infections caused by Gram positive bacteria that is forecast to reach sales of $128.2 million in 2013.

Thomson Reuters has also identified some of the promising drugs entering the various stages of clinical testing. Again, many treatments for niche conditions are featured including a treatment developed by ERYtech for acute lymphoblastic leukemia, which is entering Phase III trials and has orphan status in the US and the EU. A treatment for thymic cancer, which currently has no standard approved treatment at all, is also being investigated in a Phase II trial by Nerviano Medical Sciences

As well as orphan drugs, Thomson Reuters added that drugs for cancer continue to attract significant attention, with 25% of the quarter's promising drugs being for oncological indications. Interestingly, the report also showed that companies are looking at lifestyle fatcors that may lead to cancer; for instance, Nabi Biopharmaceuticals' NicVAX for Nicotine addiction has entered Phase III clinical trials, while a treatment for alcohol addiction, developed by Alkermes under license from Rensselaer Polytechnic Institute, has entered Phase II trials.

http://science.thomsonreuters.com


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here